ReviewJournal of neuro-oncology2019
Evidence-based dexamethasone dosing in malignant brain tumors: what do we really know?
Review in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.Neuro-oncology · 2021Pooled it
- Early withdrawal of systemic corticosteroid following malignant glioma craniotomy: a real-world population-based cohort study.Journal of neuro-oncology · 2026Article
- The role of dexamethasone during treatment phases in glioblastoma: Insights from a retrospective observational study.Brain & spine · 2026Article
- Palliative patients who may benefit from intranasal delivery of symptomatic drugs: a two-center observational study evaluated the administration of morphine and dexamethasone in Polish hospices.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Observational
- Nanoparticle-in-Hydrogel Delivery System for the Sequential Release of Two Drugs.Pharmaceutics · 2025Article
- Corticosteroids in lung cancer.Frontiers in drug safety and regulation · 2025Review
- Dexamethasone-associated regression of glioblastoma.Surgical neurology international · 2025Article
- Treatment decisions for intermediate-sized brain metastases in or near the motor cortex among the neuro-oncology community.Brain & spine · 2025Article
- Palliative care for children with central nervous system tumors: results of a Spanish multicenter study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.Frontiers in immunology · 2024Review
- Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms.Frontiers in oncology · 2023Article
- A 10-year retrospective observational study on the utility and prescription standards of dexamethasone in pediatric neuro-oncosurgery in a tertiary care center.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Observational
- Diplopia outcomes following stereotactic radiosurgery for petroclival or cavernous sinus meningiomas: patient series.Journal of neurosurgery. Case lessons · 2022Article
- Evaluation of Surgical Cleavage Plane by Preoperative Magnetic Resonance Imaging Findings in Adult Intracranial Meningiomas.Life (Basel, Switzerland) · 2022Article
- Impact of postoperative dexamethasone on survival, steroid dependency, and infections in newly diagnosed glioblastoma patients.Neuro-oncology practice · 2021Article
- Neutrophil-to-lymphocyte ratio, Factor VIII and Antithrombin III: inflammatory-clotting biomarkers in glioma.EXCLI journal · 2021Article
- Supratentorial brain tumors: Are there indications for urgent resection?Surgical neurology international · 2021Article
- Current approaches to the management of brain metastases.Nature reviews. Clinical oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe present study aims to conduct a systematic review of literature reporting on the dose and dosing schedule of dexamethasone (DXM) in relation to clinical outcomes in malignant brain tumor patients, with particular attention to evidence-based practice.
methodsA systematic search was performed in PubMed, Embase, Web of Science, Cochrane, Academic Search Premier, and PsycINFO to identify studies that reported edema volume reduction, symptomatic relief, adverse events and survival in relation to dexamethasone dose in glioma or brain metastasis (BM) patients.
resultsAfter screening 1812 studies, fifteen articles were included for qualitative review. Most studies reported a dose of 16 mg, mostly in a schedule of 4 mg four times a day. Due to heterogeneity of studies, it was not possible to perform quantitative meta-analysis. For BMs, best available evidence suggests that higher doses of DXM may give more adverse events, but may not necessarily result in better clinical condition. Some studies suggest that higher DXM doses are associated with shorter survival in the palliative setting. For glioma, DXM may lead to symptomatic improvement, yet no studies directly compare different doses. Results regarding edema reduction and survival in glioma patients are conflicting.
conclusionsEvidence on the safety and efficacy of different DXM doses in malignant brain tumor patients is scarce and conflicting. Best available evidence suggests that low DXM doses may be noninferior to higher doses in certain circumstances, but more comparative research in this area is direly needed, especially in light of the increasing importance of immunotherapy for brain tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.